PILMAN » low http://www.tapanray.in A Tapan Ray Website Sun, 22 Mar 2026 10:59:18 +0000 en-US hourly 1 http://wordpress.org/?v=3.4.2 Why Pharma Need To Connect Better With Patient Organizations Now? http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/?utm_source=rss&utm_medium=rss&utm_campaign=pharma-need-to-connect-with-patient-organizations-more-than-ever-before http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/#comments Mon, 09 Aug 2021 00:00:02 +0000 Tapan Ray http://www.tapanray.in/?p=10564 Continue reading →]]> http://www.tapanray.in/pharma-need-to-connect-with-patient-organizations-more-than-ever-before/feed/ 0 National Health Policy 2017: Some Silver Linings, Some Trepidation http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/?utm_source=rss&utm_medium=rss&utm_campaign=national-health-policy-2017-some-silver-linings-some-trepidation http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/#comments Mon, 27 Mar 2017 00:00:58 +0000 Tapan Ray http://www.tapanray.in/?p=8158 Continue reading →]]> http://www.tapanray.in/national-health-policy-2017-some-silver-linings-some-trepidation/feed/ 0 Immunization Still Remains A Low-Budget Neglected Area In India http://www.tapanray.in/immunization-still-remains-a-low-budget-neglected-area-in-india/?utm_source=rss&utm_medium=rss&utm_campaign=immunization-still-remains-a-low-budget-neglected-area-in-india http://www.tapanray.in/immunization-still-remains-a-low-budget-neglected-area-in-india/#comments Sun, 18 Dec 2016 22:46:33 +0000 Tapan Ray http://www.tapanray.in/?p=8012 Continue reading →]]> http://www.tapanray.in/immunization-still-remains-a-low-budget-neglected-area-in-india/feed/ 0 More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&utm_medium=rss&utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments Mon, 15 Apr 2013 00:00:04 +0000 Tapan Ray http://www.tapanray.in/?p=2164 Continue reading →]]> http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/ 0 Should high prices of new drugs, causing low access to majority of patients, be attributed to high R&D cost? http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/?utm_source=rss&utm_medium=rss&utm_campaign=should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/#comments Mon, 13 Feb 2012 00:00:19 +0000 Tapan Ray http://tapanray.in/index.php/?p=134 Continue reading →]]> http://www.tapanray.in/should-high-prices-of-new-drugs-causing-low-access-to-majority-of-patients-be-attributed-to-high-rd-cost/feed/ 0